TFG Asset Management GP Ltd Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

TFG Asset Management GP Ltd bought a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 41,250 shares of the company’s stock, valued at approximately $3,490,000. Axsome Therapeutics comprises approximately 0.9% of TFG Asset Management GP Ltd’s investment portfolio, making the stock its 17th biggest holding. TFG Asset Management GP Ltd owned 0.09% of Axsome Therapeutics at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Raiffeisen Bank International AG bought a new position in Axsome Therapeutics in the 4th quarter valued at $51,000. Assetmark Inc. bought a new position in Axsome Therapeutics in the 4th quarter valued at $52,000. R Squared Ltd bought a new position in Axsome Therapeutics in the 4th quarter valued at $64,000. Aquatic Capital Management LLC bought a new position in Axsome Therapeutics in the 4th quarter valued at $76,000. Finally, KBC Group NV grew its position in Axsome Therapeutics by 40.5% in the 4th quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after acquiring an additional 385 shares during the last quarter. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Trading Up 0.3%

Shares of NASDAQ AXSM opened at $107.53 on Friday. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The stock has a market capitalization of $5.29 billion, a P/E ratio of -17.95 and a beta of 0.46. Axsome Therapeutics, Inc. has a 1-year low of $64.11 and a 1-year high of $139.13. The business has a fifty day moving average price of $110.49 and a 200 day moving average price of $105.18.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. The firm had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. Equities research analysts expect that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on AXSM shares. Cantor Fitzgerald raised Axsome Therapeutics to a “strong-buy” rating in a research report on Wednesday. Leerink Partners upped their price objective on Axsome Therapeutics from $110.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, February 10th. Truist Financial upped their price objective on Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Jefferies Financial Group initiated coverage on Axsome Therapeutics in a research report on Monday, April 7th. They set a “buy” rating and a $200.00 price target on the stock. Finally, Bank of America raised their price target on Axsome Therapeutics from $143.00 to $167.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Axsome Therapeutics currently has an average rating of “Buy” and a consensus target price of $172.14.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.